Bio-Rad Laboratories, Inc.BIO

NYSEHealthcareLaboratory Analytical Instruments
Price (close)
$381.00
Market cap
$10.2B
P/E
45.9x
Revenue (TTM)
$2.6B
Net income
$222.4M
Dividend yield
—
1-year total return
40.9%
Net margin
8.6%
Revenue growth
1.4%
Debt / equity
0.11x

What Bio-Rad Laboratories, Inc. does.

Bio-Rad Laboratories, Inc. (referred to in this report as “Bio-Rad,” “we,” “us,” “the Company,” and “our”) is a multinational life science and clinical diagnostics company that develops, manufactures, and markets a broad portfolio of instruments, systems, reagents, and consumables.

We have direct operations in over 36 countries outside the United States through subsidiaries focused on sales, customer service, and product distribution. In certain locations outside and within these countries, our sales efforts are supplemented by distributors and agents.

Bio-Rad operates in two industry segments designated as Life Science and Clinical Diagnostics. Both segments operate worldwide. Our Life Science segment and our Clinical Diagnostics segment generated approximately 40% and 60%, respectively, of our consolidated net sales for the year ended December 31, 2025. We generated approximately 40% of our consolidated net sales for the year ended December 31, 2025 from the U.S. and approximately 60% from our international locations, with Europe being our largest international region.

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue$2.5B$2.9B$2.8B$2.7B$2.6B$2.6B
Net income$3.8B$4.3B-$3.6B-$637.3M-$1.8B$759.9M
Free cash flow$476.4M$535.7M$81.6M$218.2M$289.6M$374.6M

More on BIO.

Figures from Bio-Rad Laboratories, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.